Provided by Tiger Fintech (Singapore) Pte. Ltd.

Phathom Pharmaceuticals

4.03
-0.1950-4.62%
Post-market: 4.030.00000.00%19:40 EDT
Volume:956.15K
Turnover:3.94M
Market Cap:275.56M
PE:-0.76
High:4.30
Open:4.30
Low:4.02
Close:4.23
Loading ...

Company Profile

Company Name:
Phathom Pharmaceuticals
Exchange:
NASDAQ
Establishment Date:
2018
Employees:
427
Office Location:
100 Campus Drive,Suite 102,Florham Park,New Jersey,United States
Zip Code:
07932
Fax:
- -
Introduction:
Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Directors

Name
Position
Tadataka Yamada
Chairman of the Board
Terrie Curran
President, Chief Executive Officer and Director
David Socks
Interim Chief Financial Officer and Treasurer and Director
Asit Parikh
Director
Heidi Kunz
Director
James Topper
Director
Jonathan Edwards
Director
Mark Stenhouse
Director
Michael F. Cola
Director

Shareholders

Name
Position
Terrie Curran
President, Chief Executive Officer and Director
Azmi Nabulsi
Chief Operating Officer
David Socks
Interim Chief Financial Officer and Treasurer and Director
Aditya Kohli
Chief Business Officer